Friday, May 9, 2025 - 2:00 pm – 2:45 pm

DR. DAVID C. W. LAU LECTURESHIP

The Evolving Landscape of GLP-1 Medicines

Learning Objectives:

• Outline the mechanisms of action of GLP-1 medicines
• Highlight key clinical trial results supporting use of GLP-1 Medicines
• Identify emerging investigational GLP-1 medicines in late stage development

Speaker:

Dr. Daniel Drucker, OC, MD, FRCPC, FRSC, FRS

Department of Medicine
University of Toronto

Dr. Daniel J. Drucker is University Professor in the Department of Medicine’s Division of Endocrinology, the Banting and Best Diabetes Centre-Novo Nordisk Chair in Incretin Biology, and a Senior Investigator at Sinai Health’s Lunenfeld-Tanenbaum Research Institute.  

Dr. Drucker is renowned for his breakthrough discoveries of the biological actions of glucagon-like peptide hormone GLP-1, including its key roles in stimulating insulin secretion and reducing food intake. His research has helped to lay the biological foundations for the pharmacological revolution of GLP-1 based medicines that have transformed the treatment of type 2 diabetes and obesity. His discovery of the role of GLP-2 in intestinal barrier function has also led to a first-in-class, life-changing treatment for patients with short-bowel syndrome.